MCID: OLG002
MIFTS: 67

Oligodendroglioma

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Oligodendroglioma

MalaCards integrated aliases for Oligodendroglioma:

Name: Oligodendroglioma 12 52 58 29 54 6 43 15 17 71
Oligodendroglial Neoplasm 12 71
Oligodendroglial Tumor 12 58
Well Differentiated Oligodendroglioma 71
Oligodendroglial Tumors 54

Characteristics:

Orphanet epidemiological data:

58
oligodendroglioma
Inheritance: Not applicable; Age of onset: All ages;
oligodendroglial tumor
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3181
MeSH 43 D009837
SNOMED-CT 67 73348003
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0028945
UMLS 71 C0028945 C0751396 C1335110

Summaries for Oligodendroglioma

NIH Rare Diseases : 52 Oligodendrogliomas are brain tumors arising from oligodendrocytes, a type of cell that makes up the supportive (glial) tissue of the brain. They can be low-grade (grade II) or high-grade (grade III, also called anaplastic). While they can be found anywhere within the cerebral hemisphere, they are most common in the frontal and temporal lobes. They are generally soft, grayish-pink tumors that often contain mineral deposits (calcifications), areas of hemorrhage, and/or cysts. They tend to grow slowly and may be present for many years before they are diagnosed. Common symptoms include seizures , headaches and changes in personality. Other symptoms vary by the size and location of the tumor. The exact cause of opigodendrogliomas is unknown. Some appear to have a chromosome abnormality involving loss of chromosomes 1p and 19q. Treatment generally involves surgical removal of the tumor followed by radiation therapy and/or chemotherapy . Recurrent tumors may need additional surgery, radiation and chemotherapy.

MalaCards based summary : Oligodendroglioma, also known as oligodendroglial neoplasm, is related to adult oligodendroglioma and childhood oligodendroglioma. An important gene associated with Oligodendroglioma is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Dabrafenib and Trametinib have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and temporal lobe, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the... more...

Related Diseases for Oligodendroglioma

Diseases in the Oligodendroglioma family:

Adult Oligodendroglioma

Diseases related to Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 477)
# Related Disease Score Top Affiliating Genes
1 adult oligodendroglioma 34.9 OLIG2 IDH2 IDH1
2 childhood oligodendroglioma 34.8 OLIG2 MGMT IDH2 IDH1 ATRX
3 anaplastic oligodendroglioma 34.8 POT1 OLIG2 OLIG1 MGMT IDH2 CDKN2C
4 spinal cord oligodendroglioma 34.5 TP53 SYP MGMT IDH1 GFAP EGFR
5 oligoastrocytoma 34.4 MGMT IDH2 GFAP
6 mixed oligodendroglioma-astrocytoma 34.2 TP53 PTEN MGMT IDH2 IDH1 CDKN2B
7 glioma susceptibility 1 34.1 TP53 PTEN OLIG2 MGMT IDH2 IDH1
8 glial tumor 33.7 PTEN OLIG2 IDH1
9 glioma 33.3 TP53 PTEN POT1 IDH2 IDH1 EGFR
10 central neurocytoma 31.9 SYP OLIG2 GFAP
11 dysembryoplastic neuroepithelial tumor 31.8 SYP OLIG2 IDH1 GFAP
12 juvenile pilocytic astrocytoma 31.6 SYP PTEN OLIG2 MGMT IDH1 GFAP
13 extraventricular neurocytoma 31.6 SYP IDH1 GFAP
14 benign ependymoma 31.5 SYP MGMT GFAP EGFR CDKN2B
15 clear cell ependymoma 31.5 SYP OLIG2 IDH1 GFAP
16 mixed glioma 31.5 TP53 PTEN OLIG2 MGMT IDH2 IDH1
17 glioblastoma multiforme 31.5 TP53 SYP PTEN MGMT IDH2 IDH1
18 hydrocephalus 31.4 TP53 SYP PTEN MBP GFAP
19 malignant glioma 31.4 TP53 PTEN MGMT GFAP EGFR CDKN2A
20 teratoma 31.4 TP53 SYP PTEN GFAP CDKN2A
21 gangliocytoma 31.4 SYP PTEN GFAP
22 ganglioglioma 31.4 TP53 SYP IDH1 GFAP
23 angiocentric glioma 31.3 SYP IDH1 GFAP
24 cystic teratoma 31.2 TP53 SYP PTEN GFAP CDKN2A
25 meningioma, familial 31.2 TP53 SYP PTEN MGMT IDH1 GFAP
26 fibrillary astrocytoma 31.2 TP53 PTEN OLIG2 MGMT IDH2 IDH1
27 astroblastoma 31.2 SYP IDH1 GFAP
28 low-grade astrocytoma 31.0 TP53 IDH1 CDKN2B CDKN2A
29 gemistocytic astrocytoma 31.0 TP53 PTEN MGMT IDH2 IDH1 GFAP
30 enchondroma 31.0 IDH2 IDH1
31 pleomorphic xanthoastrocytoma 31.0 TP53 SYP MGMT IDH1 GFAP ATRX
32 anaplastic ependymoma 30.9 SYP PTEN GFAP
33 neuroblastoma 30.9 TP73 TP53 SYP PTEN GFAP EGFR
34 gliomatosis cerebri 30.9 TP53 SYP PTEN IDH1 GFAP EGFR
35 obstructive hydrocephalus 30.9 SYP OLIG2 GFAP
36 pilomyxoid astrocytoma 30.9 SYP IDH2 IDH1 GFAP ATRX
37 cerebral neuroblastoma 30.9 SYP GFAP
38 adenoma 30.8 TP53 SYP MGMT CDKN2A
39 gliosarcoma 30.8 TP53 SYP PTEN OLIG2 MGMT IDH2
40 myeloma, multiple 30.8 TP53 PTEN IDH2 IDH1 FLT1 EGFR
41 grade iii astrocytoma 30.8 TP73 TP53 PTEN OLIG2 OLIG1 MGMT
42 brain glioma 30.7 TP53 PTEN MGMT IDH2 IDH1 GFAP
43 brain cancer 30.7 TP73 TP53 SYP PTEN OLIG2 OLIG1
44 lymphoma 30.7 TP53 MGMT EGFR CDKN2C CDKN2B CDKN2A
45 lynch syndrome 30.7 TP73 TP53 PTEN MGMT EGFR CDKN2B
46 leukemia, acute lymphoblastic 30.7 TP73 TP53 CDKN2C CDKN2B CDKN2A
47 malignant ependymoma 30.6 TP53 MGMT IDH1 GFAP EGFR
48 adult astrocytic tumour 30.6 TP53 PTEN IDH2 IDH1 CDKN2A ATRX
49 tuberous sclerosis 30.6 TP53 SYP PTEN GFAP
50 thymoma 30.6 TP53 SYP EGFR CDKN2A

Graphical network of the top 20 diseases related to Oligodendroglioma:



Diseases related to Oligodendroglioma

Symptoms & Phenotypes for Oligodendroglioma

GenomeRNAi Phenotypes related to Oligodendroglioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.55 CDKN2A CIC GMNN POT1 PTEN TP73
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.55 CDKN2A CIC GMNN POT1 PTEN TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.55 CIC POT1 TP53 TP73

MGI Mouse Phenotypes related to Oligodendroglioma:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 ATRX CDKN2A CDKN2C CIC FLT1 GFAP
2 cellular MP:0005384 10.38 ATRX CDKN2A CDKN2B CDKN2C EGFR FLT1
3 mortality/aging MP:0010768 10.36 ATRX CDKN2A CDKN2B CDKN2C CIC EGFR
4 growth/size/body region MP:0005378 10.34 ATRX CDKN2A CDKN2C CIC EGFR FLT1
5 homeostasis/metabolism MP:0005376 10.27 CDKN2A CDKN2B CDKN2C EGFR FLT1 GFAP
6 cardiovascular system MP:0005385 10.25 ATRX CDKN2A CDKN2C EGFR FLT1 GFAP
7 hematopoietic system MP:0005397 10.22 CDKN2A CDKN2B CDKN2C EGFR FLT1 GMNN
8 nervous system MP:0003631 10.22 ATRX CDKN2A CDKN2C CIC EGFR FLT1
9 immune system MP:0005387 10.21 CDKN2A CDKN2B CDKN2C EGFR FLT1 GFAP
10 embryo MP:0005380 10.18 ATRX CDKN2A EGFR FLT1 GMNN POT1
11 endocrine/exocrine gland MP:0005379 10.16 CDKN2A CDKN2B CDKN2C EGFR GMNN MGMT
12 neoplasm MP:0002006 10.07 CDKN2A CDKN2B CDKN2C EGFR IDH2 MGMT
13 reproductive system MP:0005389 9.9 ATRX CDKN2A CDKN2B CDKN2C EGFR FLT1
14 no phenotypic analysis MP:0003012 9.8 CDKN2A CDKN2B EGFR MGMT OLIG2 POT1
15 respiratory system MP:0005388 9.65 CDKN2A CDKN2C CIC EGFR IDH1 MGMT
16 vision/eye MP:0005391 9.36 ATRX CDKN2A EGFR FLT1 GFAP GMNN

Drugs & Therapeutics for Oligodendroglioma

Drugs for Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 324)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
2
Trametinib Approved Phase 4 871700-17-3 11707110
3
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
6
Etoposide Approved Phase 3 33419-42-0 36462
7
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
8
leucovorin Approved Phase 3 58-05-9 6006 143
9
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
10
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
11
Donepezil Approved Phase 3 120014-06-4 3152
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
16
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
17
Histamine Approved, Investigational Phase 3 51-45-6 774
18
Cyproheptadine Approved Phase 3 129-03-3 2913
19
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
20
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
22 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
23 Immunosuppressive Agents Phase 3
24 Etoposide phosphate Phase 3
25 Antirheumatic Agents Phase 3
26 Folic Acid Antagonists Phase 3
27 Vitamin B Complex Phase 3
28 Folate Phase 3
29 Vitamin B9 Phase 3
30 Liver Extracts Phase 3
31 Emetics Phase 3
32 Analgesics Phase 3
33 Cholinesterase Inhibitors Phase 3
34 Cholinergic Agents Phase 3
35 Anesthetics Phase 3
36 Cola Phase 3
37 Narcotics Phase 3
38 Analgesics, Opioid Phase 3
39 Anesthetics, General Phase 3
40 Anesthetics, Intravenous Phase 3
41 Tubulin Modulators Phase 3
42 Antimitotic Agents Phase 3
43 Neurotransmitter Agents Phase 3
44 Central Nervous System Stimulants Phase 3
45 Histamine Antagonists Phase 3
46 Anti-Allergic Agents Phase 3
47
Histamine Phosphate Phase 3 51-74-1 65513
48 Histamine H1 Antagonists Phase 3
49 Dopamine Agents Phase 3
50 Dexmethylphenidate Hydrochloride Phase 3

Interventional clinical trials:

(show top 50) (show all 384)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
3 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
4 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
5 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
6 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
7 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
8 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
9 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
10 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
11 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
12 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 A Randomized Trial of Delayed Radiotherapy in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Oligodendroglial Tumors: the POLCA Trial. Recruiting NCT02444000 Phase 3 PCV chemotherapy alone;Radiotherapy+PCV chemotherapy
14 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
15 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
16 Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas Active, not recruiting NCT00978458 Phase 3 temozolomide
17 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
18 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
19 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
20 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
21 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
22 A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Withdrawn NCT04105374 Phase 2, Phase 3 Extended Release Flucytosine;Temozolomide
23 A Phase II Study of Temozolomide in the Treatment of Recurrent Malignant Gliomas Unknown status NCT00004204 Phase 2 temozolomide
24 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
25 A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
26 A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
27 A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Low-grade Glioma Unknown status NCT01635283 Phase 2
28 A Prospective, Multicentre Trial on the Value of 18F-FET PET in the Post-therapeutic Evaluation of Childhood Brain Tumours Unknown status NCT03216148 Phase 2
29 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
30 Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
31 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
32 First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial Completed NCT00003731 Phase 2 temozolomide
33 Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy Completed NCT00003304 Phase 2 temozolomide
34 Phase II Treatment of Adults and Children With Progressive Low Grade Gliomas With Temodal Completed NCT00003466 Phase 2 temozolomide
35 Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Completed NCT02530320 Phase 2 Palbociclib
36 Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal Completed NCT00003465 Phase 2 temozolomide
37 The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
38 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma Completed NCT00400816 Phase 2 temozolomide
39 A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma Completed NCT00003372 Phase 2 topotecan hydrochloride
40 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
41 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
42 Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
43 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
44 Immunotherapy for Malignant Glioma - Phase II Trial of Autologous Cancer Antigen Specific Immunotherapy Completed NCT00004024 Phase 2
45 A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
46 Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma Completed NCT00006080 Phase 2 fenretinide
47 Phase II Study of Antineoplastons A10 and AS2-1 in Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
48 Efficacy of a Protracted Temozolomide Schedule in Patients With Progression After Standard Dose Temozolomide for High-grade Gliomas Completed NCT00575887 Phase 2 Temozolomide
49 A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
50 Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant

Search NIH Clinical Center for Oligodendroglioma

Cochrane evidence based reviews: oligodendroglioma

Genetic Tests for Oligodendroglioma

Genetic tests related to Oligodendroglioma:

# Genetic test Affiliating Genes
1 Oligodendroglioma 29

Anatomical Context for Oligodendroglioma

MalaCards organs/tissues related to Oligodendroglioma:

40
Brain, Spinal Cord, Temporal Lobe, Bone, T Cells, Breast, Endothelial

Publications for Oligodendroglioma

Articles related to Oligodendroglioma:

(show top 50) (show all 2733)
# Title Authors PMID Year
1
Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. 54 61
19967449 2010
2
Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma. 54 61
20052522 2009
3
Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. 54 61
19934553 2009
4
[Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma]. 54 61
19781190 2009
5
[Common mechanism underlying oligodendrocyte development and oligodendrogliomagenesis]. 61 54
19618851 2009
6
Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. 61 54
19357963 2009
7
Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. 61 54
19346643 2009
8
p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. 61 54
19240607 2009
9
[Expression of myelin basic protein and glial fibrillary acidic protein genes in human glial brain tumors]. 54 61
19663312 2009
10
Oligodendrogliomas in relation to astrocytes differentiation. Clinicopathologic and immunohistochemical study. 54 61
18774492 2008
11
[Radiotherapy of adult glial tumors: new developments and perspectives]. 54 61
18565351 2008
12
Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. 61 54
18552083 2008
13
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. 61 54
17435181 2007
14
Receptor-targeted quantum dots: fluorescent probes for brain tumor diagnosis. 54 61
17867825 2007
15
Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. 54 61
17415208 2007
16
Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. 61 54
17319279 2007
17
Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. 54 61
17146289 2006
18
Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. 54 61
16874663 2006
19
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. 54 61
16541434 2006
20
Survival analysis of presumptive prognostic markers among oligodendrogliomas. 61 54
16116609 2005
21
OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1. 54 61
16103065 2005
22
Correlation of glial fibrillary acidic protein (GFAP) with grading of the neuroglial tumours. 61 54
16202357 2005
23
Ceramide regulation of the tumor suppressor phosphatase PTEN in rafts isolated from neurotumor cell lines. 61 54
15968641 2005
24
Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. 61 54
15834925 2005
25
Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas. 54 61
15899783 2005
26
Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression. 54 61
16038527 2005
27
Mutational study of the 1p located genes p18ink4c, Patched-2, RIZ1 and KIF1B in oligodendrogliomas. 61 54
15711769 2005
28
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. 61 54
15455350 2005
29
Gene expression profiling and subgroup identification of oligodendrogliomas. 61 54
15208679 2004
30
Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. 54 61
15118874 2004
31
p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. 61 54
15269478 2004
32
Acid sphingomyelinase and inhibition by phosphate ion: role of inhibition by phosphatidyl-myo-inositol 3,4,5-triphosphate in oligodendrocyte cell signaling. 54 61
15086520 2004
33
Heterogeneity in the expression of markers for drug resistance in brain tumors. 54 61
14986930 2004
34
Transcriptional regulation of the human UDP-galactose:ceramide galactosyltransferase (hCGT) gene expression: functional role of GC-box and CRE. 61 54
15229398 2004
35
Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. 54 61
14507338 2003
36
Expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in oligodendrogliomas in humans. 54 61
12873740 2003
37
Genetic determinants of malignancy in a mouse model for oligodendroglioma. 54 61
12670909 2003
38
CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. 54 61
12556968 2003
39
Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors. 54 61
12507133 2002
40
Galectin-3 labeling correlates positively in tumor cells and negatively in endothelial cells with malignancy and poor prognosis in oligodendroglioma patients. 54 61
12168841 2002
41
Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. 61 54
11929835 2002
42
Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. 54 61
11801559 2002
43
Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome. 54 61
11800646 2002
44
Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. 61 54
11557779 2001
45
Mutation analysis of the p73 gene in nonastrocytic brain tumours. 61 54
11461077 2001
46
The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas. 61 54
11419973 2001
47
Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas. 54 61
11322447 2001
48
Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. 54 61
11307615 2001
49
Hamartin expression and interaction with tuberin in tumor cell lines and primary cultures. 61 54
11170177 2001
50
Analysis of 2 antiapoptotic factors in gliomas: bcl-2 overexpression and p53 mutations. 61 54
11175638 2001

Variations for Oligodendroglioma

ClinVar genetic disease variations for Oligodendroglioma:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IDH1 NM_001282386.1(IDH1):c.395G>A (p.Arg132His)SNV Pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
2 CIC NM_015125.4(CIC):c.290_291insT (p.Gly99fs)insertion Likely pathogenic 635171 rs1568503055 19:42791230-42791231 19:42287078-42287079
3 ATRX NM_000489.5(ATRX):c.4213A>G (p.Arg1405Gly)SNV Uncertain significance 635172 rs1569535987 X:76912051-76912051 X:77656561-77656561

Cosmic variations for Oligodendroglioma:

9 (show top 50) (show all 19848)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263021 ZRSR2 central nervous system,brain,glioma,anaplastic c.260G>A p.R87K 23:15803744-15803744 4
2 COSM88262556 ZRSR2 central nervous system,brain,glioma,oligodendroglioma c.220G>A p.E74K 23:15803704-15803704 4
3 COSM149299313 ZFHX3 central nervous system,brain,glioma,anaplastic c.145C>T p.P49S 16:72960001-72960001 4
4 COSM149332069 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.2680G>A p.D894N 16:72957466-72957466 4
5 COSM149332063 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.9154G>A p.V3052I 16:72793528-72793528 4
6 COSM149268215 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.6025T>C p.Y2009H 16:72796657-72796657 4
7 COSM149261414 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.8300G>A p.G2767E 16:72794382-72794382 4
8 COSM149260463 ZFHX3 central nervous system,brain,glioma,anaplastic c.8647A>G p.M2883V 16:72794035-72794035 4
9 COSM149318917 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.8600C>T p.S2867F 16:72794082-72794082 4
10 COSM149290610 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.3986G>A p.G1329E 16:72798696-72798696 4
11 COSM152022282 YES1 central nervous system,brain,glioma,oligodendroglioma c.259G>C p.A87P 18:756569-756569 4
12 COSM143036045 YAP1 central nervous system,brain,glioma,oligodendroglioma c.1024G>A p.A342T 11:102209544-102209544 4
13 COSM94291565 XIAP central nervous system,brain,glioma,anaplastic c.1057-2A>T p.? 23:123892729-123892729 4
14 COSM91365167 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 4
15 COSM96870342 VTCN1 central nervous system,brain,glioma,anaplastic c.404C>T p.S135F 1:117156615-117156615 4
16 COSM131097528 TSHR central nervous system,brain,glioma,oligodendroglioma c.1765C>T p.L589F 14:81143823-81143823 4
17 COSM131084541 TSHR central nervous system,brain,glioma,anaplastic c.1493G>A p.G498D 14:81143551-81143551 4
18 COSM131089332 TSHR central nervous system,brain,glioma,oligodendroglioma c.1560G>A p.W520* 14:81143618-81143618 4
19 COSM87027285 TSC2 central nervous system,brain,glioma,oligodendroglioma c.3131G>A p.R1044K 16:2079196-2079196 4
20 COSM87029262 TSC2 central nervous system,brain,glioma,anaplastic c.3124C>T p.P1042S 16:2079189-2079189 4
21 COSM87028719 TSC2 central nervous system,brain,glioma,anaplastic c.574G>T p.D192Y 16:2055494-2055494 4
22 COSM85724312 TSC1 central nervous system,brain,glioma,anaplastic c.913+1G>A p.? 9:132912281-132912281 4
23 COSM90145640 TRAF7 central nervous system,brain,glioma,oligodendroglioma c.1189G>A p.G397S 16:2173974-2173974 4
24 COSM90144693 TRAF7 central nervous system,brain,glioma,oligodendroglioma c.1898T>C p.M633T 16:2176284-2176284 4
25 COSM88645352 TP63 central nervous system,brain,glioma,oligodendroglioma c.437C>T p.P146L 3:189808384-189808384 4
26 COSM87899497 TP53 central nervous system,brain,glioma,anaplastic c.586C>T p.R196* 17:7674945-7674945 4
27 COSM87898723 TP53 central nervous system,brain,glioma,anaplastic c.817C>T p.R273C 17:7673803-7673803 4
28 COSM87897752 TP53 central nervous system,brain,glioma,anaplastic c.731G>A p.G244D 17:7674232-7674232 4
29 COSM87905621 TP53 central nervous system,brain,glioma,anaplastic c.470T>G p.V157G 17:7675142-7675142 4
30 COSM87953047 TP53 central nervous system,brain,glioma,anaplastic c.490A>T p.K164* 17:7675122-7675122 4
31 COSM87944274 TP53 central nervous system,brain,glioma,anaplastic c.419C>T p.T140I 17:7675193-7675193 4
32 COSM87907695 TP53 central nervous system,brain,glioma,oligodendroglioma c.518T>C p.V173A 17:7675094-7675094 4
33 COSM88043173 TP53 central nervous system,brain,glioma,oligodendroglioma c.719G>C p.S240T 17:7674244-7674244 4
34 COSM87947300 TP53 central nervous system,brain,glioma,anaplastic c.96+1G>T p.? 17:7676381-7676381 4
35 COSM87897924 TP53 central nervous system,brain,glioma,anaplastic c.413C>T p.A138V 17:7675199-7675199 4
36 COSM87897850 TP53 central nervous system,brain,glioma,anaplastic c.833C>G p.P278R 17:7673787-7673787 4
37 COSM87911029 TP53 central nervous system,brain,glioma,oligodendroglioma c.623A>T p.D208V 17:7674908-7674908 4
38 COSM87906483 TP53 central nervous system,brain,glioma,anaplastic c.785G>T p.G262V 17:7673835-7673835 4
39 COSM87902396 TP53 central nervous system,brain,glioma,oligodendroglioma c.405C>G p.C135W 17:7675207-7675207 4
40 COSM87905937 TP53 central nervous system,brain,glioma,anaplastic c.332T>G p.L111R 17:7676037-7676037 4
41 COSM87900846 TP53 central nervous system,brain,glioma,anaplastic c.380C>T p.S127F 17:7675232-7675232 4
42 COSM87985869 TP53 central nervous system,brain,glioma,anaplastic c.403T>G p.C135G 17:7675209-7675209 4
43 COSM87899695 TP53 central nervous system,brain,glioma,anaplastic c.715A>G p.N239D 17:7674248-7674248 4
44 COSM87905366 TP53 central nervous system,brain,glioma,anaplastic c.476C>T p.A159V 17:7675136-7675136 4
45 COSM87905487 TP53 central nervous system,brain,glioma,oligodendroglioma c.721T>G p.S241A 17:7674242-7674242 4
46 COSM87899842 TP53 central nervous system,brain,glioma,anaplastic c.584T>C p.I195T 17:7674947-7674947 4
47 COSM87935614 TP53 central nervous system,brain,glioma,oligodendroglioma c.738G>A p.M246I 17:7674225-7674225 4
48 COSM87922945 TP53 central nervous system,brain,glioma,anaplastic c.394A>C p.K132Q 17:7675218-7675218 4
49 COSM88080641 TP53 central nervous system,brain,glioma,anaplastic c.531C>T p.P177= 17:7675081-7675081 4
50 COSM87899887 TP53 central nervous system,brain,glioma,oligodendroglioma c.856G>A p.E286K 17:7673764-7673764 4

Copy number variations for Oligodendroglioma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13342 1 1 124300000 Loss Oligodendroglial tumors
2 42816 10 40300000 135374737 Loss Oligodendroglial tumors
3 119741 18 16100000 76117153 Loss Oligodendroglial tumors
4 124095 19 1 28500000 Gain Oligodendroglial tumors
5 127178 19 28500000 63811651 Loss Oligodendroglial tumors
6 187538 4 50700000 191273063 Loss Oligodendroglial tumors
7 217108 7 1 59100000 Gain Oligodendroglial tumors
8 226562 7 59100000 158821424 Gain Oligodendroglial tumors
9 244959 9 1 51800000 Loss Oligodendroglial tumors

Expression for Oligodendroglioma

Search GEO for disease gene expression data for Oligodendroglioma.

Pathways for Oligodendroglioma

Pathways related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1 12.73 TP53 PTEN EGFR CDKN2B CDKN2A
2
Show member pathways
12.63 TP53 PTEN EGFR CDKN2B CDKN2A
3
Show member pathways
12.4 TP53 PTEN EGFR CDKN2C CDKN2B CDKN2A
4
Show member pathways
12.27 TP73 TP53 PTEN CDKN2A
5 12.25 TP53 CDKN2C CDKN2B CDKN2A
6
Show member pathways
12.23 TP53 CDKN2C CDKN2B CDKN2A
7 12.21 TP73 TP53 MGMT GMNN CDKN2C CDKN2A
8 12.14 TP53 PTEN CDKN2C CDKN2B CDKN2A
9 12.02 TP53 PTEN CDKN2B CDKN2A
10 11.93 TP73 TP53 PTEN EGFR
11 11.87 TP53 MBP GFAP EGFR
12 11.84 TP73 TP53 PTEN CDKN2A
13 11.77 OLIG2 OLIG1 MBP GFAP
14 11.76 TP53 PTEN CDKN2B
15 11.62 TP53 EGFR CDKN2A
16 11.6 TP53 PTEN MGMT EGFR CDKN2A
17 11.57 SYP OLIG2 OLIG1 GFAP
18 11.55 TP53 PTEN ATRX
19 11.43 TP53 EGFR CDKN2A
20 11.38 TP53 PTEN CDKN2B
21
Show member pathways
10.95 TP73 TP53 CDKN2A
22 10.87 TP53 PTEN IDH2 IDH1 EGFR
23 10.76 TP53 CDKN2C CDKN2B CDKN2A
24
Show member pathways
10.73 IDH2 IDH1

GO Terms for Oligodendroglioma

Cellular components related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.5 TP73 TP53 PTEN POT1 OLIG2 OLIG1

Biological processes related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.91 TP73 TP53 GMNN CDKN2C CDKN2B CDKN2A
2 negative regulation of cell proliferation GO:0008285 9.88 TP53 PTEN CDKN2C CDKN2B CDKN2A
3 response to organic cyclic compound GO:0014070 9.67 PTEN MGMT IDH1 EGFR
4 oligodendrocyte differentiation GO:0048709 9.58 OLIG2 OLIG1 CDKN2C
5 replicative senescence GO:0090399 9.54 TP53 CDKN2A
6 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.52 TP53 EGFR
7 negative regulation of telomerase activity GO:0051974 9.51 TP53 POT1
8 NADP metabolic process GO:0006739 9.49 IDH2 IDH1
9 isocitrate metabolic process GO:0006102 9.46 IDH2 IDH1
10 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.46 PTEN CDKN2C CDKN2B CDKN2A
11 negative regulation of phosphorylation GO:0042326 9.43 CDKN2C CDKN2B CDKN2A
12 cell cycle arrest GO:0007050 9.35 TP73 TP53 CDKN2C CDKN2B CDKN2A
13 glyoxylate cycle GO:0006097 9.32 IDH2 IDH1
14 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 8.92 PTEN CDKN2C CDKN2B CDKN2A

Molecular functions related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.06 TP73 TP53 POT1 OLIG2 OLIG1 MGMT
2 identical protein binding GO:0042802 9.92 TP73 TP53 SYP PTEN OLIG2 IDH1
3 chromatin binding GO:0003682 9.83 TP53 GMNN EGFR CIC ATRX
4 MDM2/MDM4 family protein binding GO:0097371 9.37 TP73 TP53
5 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.26 IDH2 IDH1
6 protein kinase binding GO:0019901 9.17 TP73 TP53 PTEN EGFR CDKN2C CDKN2B
7 isocitrate dehydrogenase activity GO:0004448 9.16 IDH2 IDH1
8 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.13 CDKN2C CDKN2B CDKN2A

Sources for Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....